Radio-labeled receptor-binding peptides: A new class of radiopharmaceuticals

Seminars in Nuclear Medicine

Volumn 30, Issue 3, 2000, Pages 195-208

  Boerman, Otto C ^a   Oyen, Wim J G ^a   Corstens, Frans H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BOMBESIN; CALCITONIN; CHEMOTACTIC PEPTIDE; CHOLECYSTOKININ RECEPTOR; CYTOKINE; DEFENSIN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 8; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; THROMBOCYTE FACTOR 4; VITRONECTIN RECEPTOR;

BINDING AFFINITY; GENE OVEREXPRESSION; GRANULOCYTE; INFECTION; INFLAMMATION; ISOTOPE LABELING; NEPHROTOXICITY; ONCOLOGY; RADIOISOTOPE THERAPY; RECEPTOR BINDING; REVIEW; THROMBOCYTE; THROMBUS; TUMOR CELL;

EID: 0033926430     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2000.7441     Document Type: Article

References (99)

1. Reubi JC Schaer JC Waser B Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors Cancer Res 57 1997 1377 1386
2. Reubi JC Waser B Schaer JC Neurotensin receptors in human neoplasms: High incidence in Ewing's sarcomas Int J Cancer 82 1999 213 218
3. Gillespie MT Thomas RJ Pu ZY Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers Int J Cancer 73 1997 812 815
4. Reubi JC Schaer JC Markwalder R Distribution of somatostatin receptors in normal and neoplastic human tissues: Recent advances and potential relevance Yale J Biol Med 70 1997 471 479
5. Krenning EP Kwekkeboom DJ Bakker WH Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients Eur J Nucl Med 20 1993 716
6. Krenning EP de Jong M Kooij PP Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy Ann Oncol 10 suppl 2 1999 S23 S29
7. Van Eijck CHJ de Jong M Breeman WAP Somatostatin receptor imaging and therapy of pancreatic endocrine tumors Ann Oncol 10 suppl 4 1999 S177 S181
8. Gibril F Reynolds JC Doppman JL Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study Ann Intern Med 125 1996 26 34
9. Gibril F Reynolds JC Chen CC Specificity of somatostatin receptor scintigraphy: A prospective study and effects of false-positive localization on management in patients with gastrinomas J Nucl Med 40 1999 539 553
10. Bajc M Ingvar C Palmer J Dynamic indium-111-pentetreotide scintigraphy in breast cancer J Nucl Med 37 1996 622 666
11. Chiti A Agresti R Maffioli LS Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography Eur J Nucl Med 24 1997 192 196
12. Leners N Jamar F Fiasse R Indium-111-pentetreotide uptake in endocrine tumors and lymphoma J Nucl Med 37 1996 916 922
13. Sarda L Duet M Zini JM Indium-111 pentetreotide scintigraphy in malignant lymphomas Eur J Nucl Med 22 1995 1105 1109
14. de Jong M Bernard BF De Bruin E Internalization of radiolabelled [DTPA] octreotide and [DOTA0,Tyr3] octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy Nucl Med Commun 19 1998 283 288
15. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy Cancer Res 58 1998 437 441
16. de Jong M Bakker WH Krenning EP Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA,D-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy Eur J Nucl Med 24 1997 368 371
17. de Jong M Breeman WA Bernard BF Tumour uptake of the radiolabelled somatostatin analogue [DOTA, TYR3]octreotide is dependent on the peptide amount Eur J Nucl Med 26 1999 693 698
18. Otte A Herrmann R Heppeler A Yttrium-90 DOTATOC: First clinical results Eur J Nucl Med 26 1999 1439 1447
19. 90Y-DOTATOC treatment of patients with SSTR2 positive tumors: Preliminary results of phase I–II study (abstr) J Nucl Med 40 1999
20. Møgensen CE Sølling K Studies on renal tubular protein reabsorption: Partial and near complete inhibition by certain aminoacids Scand J Clin Lab Invest 37 1977 477 486
21. Behr TM Sharkey RM Juweid ME Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic aminoacids and their derivatives Cancer Res 55 1995 3825 3834
22. Kobayashi H Yoo TM Kim IS L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment Cancer Res 56 1996 3788 3795
23. de Jong M Rolleman EJ Bernard BF Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo J Nucl Med 37 1996 1388 1392
24. Bernard BF Krenning EP Breeman WA D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake J Nucl Med 38 1997 1929 1933
25. Behr TM Boerman OC Report of the 13th meeting of the International research group on immunoscintigraphy and immunotherapy (IRIST) Eur J Nucl Med 26 1999 950 952
26. Rösch F Herzog H Stolz B Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue Eur J Nucl Med 26 1999 358 366
27. 90Y-DOTATOC Eur J Nucl Med 26 1999 877 886
28. Smith-Jones PM Bischof C Leimer M DOTA-lanreotide: A novel somatostatin analog for tumor diagnosis and therapy Endocrinology 140 1999 5136 5148
29. Virgolini I Mack Forster Award Lecture. Receptor nuclear medicine: Vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients Eur J Clin Invest 27 1997 793 800
30. 261P de Jong M de Bruin E Bernard B Internalization of In-111-labeled somatostatin analogues for tumor scintigraph and radionuclide therapy (abstr) J Nucl Med 39 1998
31. Virgolini I Szilvasi I Kurtaran A Indium-111-DOTA-lanreotide: Biodistribution, safety and radiation absorbed dose in tumor patients J Nucl Med 39 1998 1928 1936
32. Leimer M Kurtaran A Smith-Jones P Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma J Nucl Med 39 1998 2090 2094
33. 19P Flores J Kurtaran A Moncayo R Diagnostic and treatment of radioiodine-negative thyroid cancer using DOTA-lanreotide (MAURITIUS) J Nucl Med 40 1999
34. Vallabhajosula S Moyer BR Lister-James J Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides J Nucl Med 37 1996 1016 1022
35. 99mTc-P829 Cancer Res 58 1998 1850 1859
36. Blum JE Handmaker H Rinne NA The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules Chest 115 1999 224 232
37. 123I-Tyr3]octreotide Eur J Nucl Med 20 1993 1089 1094
38. 111In-DTPA-D-Phe1]octreotide Eur J Nucl Med 21 1994 328 335
39. 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: Approaches with pre- and postconjugate labeling Nucl Med Biol 25 1998 621 631
40. Banks WA Schally AV Barrera CM Permeability of the murine blood brain barrier to some octapeptide analogues of somatostatin Proc Natl Acad Sci USA 10 1990 431 438
41. Decristoforo C Mather SJ Technetium-99m somatostatin analogues: Effect of labelling methods and peptide sequence Eur J Nucl Med 26 1999 869 876
42. 111In-DTPA-octreotide Eur J Nucl Med 27 2000 S87
43. Virgolini I Yang Q Li S Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors Cancer Res 54 1994 690 700
44. Virgolini I Raderer M Kurtaran A Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors N Engl J Med 331 1994 1116 1121
45. 123I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract Nucl Med Biol 23 1996 685 692
46. 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer Br J Cancer 78 1998 1 5
47. Raderer M Kurtaran A Yang Q Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer J Nucl Med 39 1998 1570 1575
48. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans J Nucl Med 41 2000 107 110
49. 125I-(Tyr4) bombesin by tumor cells Prostate 25 1994 29 38
50. Baidoo KE Lin KS Zhan Y Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues Bioconjug Chem 9 1998 218 225
51. 111In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy Int J Cancer 83 1999 657 663
52. Breeman WA Hofland LJ de Jong M Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy Int J Cancer 81 1999 658 665
53. 104P Hoffman TJ Simpson SD Smith CJ Accumulation and retention of Tc-99m RP527 by GRP receptor expressing tumors in SCID mice J Nucl Med 40 1999
54. Reubi JC Waser B Laderach U Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach Gastroenterology 112 1997 1197 1205
55. Reubi JC Schaer JC Waser B Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors Cancer Res 57 1997 1377 1386
56. Reubi JC Waser B Schaer JC Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo Eur J Nucl Med 25 1998 481 490
57. 111In-labeled nonsulfated CCK8 analog: A peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy J Nucl Med 40 1999 2081 2087
58. (suppl) Behr TM Behe M Angerstein C Cholecystokinin-B/gastrin receptor binding peptides: Preclinical development and evaluation of their diagnostic and therapeutic potential Clin Cancer Res 5 1999 3124S 3138S
59. Behr TM Jenner N Behe M Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors J Nucl Med 40 1999 1029 1044
60. 103P Nelson CA Moyer BR Pearson DA A peptide analog of calccitonin labeled with Tc-99m targets MCF-7 human breast cancer xenografts in nude mice J Nucl Med 40 1999
61. Lafrenie RM Gallo S Podor TJ The relative roles of vitronectin receptor, E-selectin and alpha 4 beta 1 in cancer cell adhesion to interleukin-1-treated endothelial cells Eur J Cancer 30A 1994 2151 2158
62. 99mTc [abstr] Proceedings of the 8th ISORBE Congress Castel Gandolfo, Rome, Italy 24–27 May 1997
63. Sivolapenko GB Skarlos D Pectasides D Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide Eur J Nucl Med 25 1998 1383 1389
64. Haubner R Wester HJ Reuning U Radiolabeled alpha(v)beta3 integrin antagonists: A new class of tracers for tumor targeting J Nucl Med 40 1999 1061 1071
65. 32P Zoghbi S Thakur M Gottschalk A Selective cell labelling: A potential radioactive agent for labeling of human neutrophils (abstr) J Nucl Med 22 1981
66. McAfee JG Subramanian G Gagne G Technique of leukocyte harvesting and labeling: Problems and perspectives Semin Nucl Med 14 1984 83 106
67. Fischman AJ Pike MC Kroon D Imaging focal sites of bacterial infection in rats with indium-111-labeled chemotactic peptide analogs J Nucl Med 32 1991 483 491
68. Babich JW Graham W Barrow SA Technetium-99m-labeled chemotactic peptides: Comparison with indium-111-labeled white blood cells for localizing acute bacterial infection in the rabbit J Nucl Med 34 1993 2176 2181
69. Fischman AJ Rauh D Solomon H In vivo bioactivity and biodistribution of chemotactic peptide analogs in nonhuman primates J Nucl Med 34 1993 2130 2134
70. Pollak A Goodbody AE Ballinger JR Imaging inflammation with Tc-99m labelled chemotactic peptides: Analogues with reduced neutropenia Nucl Med Commun 17 1996 132 139
71. Welling MM Hiemstra PS van den Barselaar MT Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation J Clin Invest 102 1998 1583 1590
72. Welling MM Nibbering PH Paulusma-Annema A Imaging of bacterial infections with 99mTc-labeled human neutrophil peptide-1 J Nucl Med 40 1999 2073 2080
73. van der Laken CJ Boerman OC Oyen WJG Specific targeting of infectious foci with radioidinated human recombinant interleukin-1 in an experimental model Eur J Nucl Med 22 1995 1249 1255
74. van der Laken CJ Boerman OC Oyen WJG Imaging of infection in rabbits with radioiodinated interleukin-1 (α and β), its receptor antagonist and a chemotactic peptide: A comparative study Eur J Nucl Med 25 1998 347 352
75. 123I-IL-ra in affected joints in patients with rheumatic arthritis 1999
76. 123I-interleukin-2 labeling procedure and animal studies Nucl Med Commun 13 1992 713 722
77. Chianelli M Signore A Fritzberg AR The development of technetium-99m-labelled interleukin-2: A new radiopharmaceutical for the invo detection of mononuclear cell infiltrates in immune-mediated diseases Nucl Med Biol 24 1997 579 586
78. Signore A Interleukin-2 scintigraphy: An overview Nucl Med Commun 20 1999 938
79. van Hagen PM Breeman WAP Reubi JC Visualization of the thymus by substance P receptor scintigraphy in man Eur J Nucl Med 23 1996 1508 1513
80. 24P van Hagen PM Ligtenauer-Kaligis EGR ten Bokum AMC Somatostatin receptor expression in clinical immunology (abstr) J Nucl Med 37 1996
81. Oyen WJ Boerman OC Claessens RA Is somatostatin receptor scintigraphy suited to detection of acute infectious disease? Nucl Med Commun 15 1994 289 293
82. Hay RV Skinner RS Newman OC Scintigraphy of acute inflammatory lesions in rats with radiolabelled recombinant human interleukin-8 Nucl Med Commun 18 1997 367 378
83. 25P Gross MD Shapiro B Skinner RS Scintigraphy of osteomyelitis in man with human recombinant interleukin-8 (abstr) J Nucl Med 37 1996
84. van der Laken CJ Boerman OC Oyen WJG Radiolabeled interleukin-8: Scintigraphic detection of infection within a few hours J Nucl Med 41 2000 463 469
85. (abstr) Rennen HJJM Boerman OC Oyen WJG Specific and rapid scintigraphic detection of infection with Tc-99m-labeled interleukin-8 Eur J Nucl Med 26 1999 1005
86. Moyer BR Vallabhajosula S Lister-James J Technetium-99m-white blood cell-specific imaging agent developed from platelet factor 4 to detect infection J Nucl Med 37 1996 673 679
87. 15P Palestro CJ Tomas MB Bhargava KK Tc-99m P483H for imaging infection: Phase 2 multicenter trial results (abstr) J Nucl Med 40 1999
88. Knight LC Radcliffe R Maurer AH Thrombus imaging with technetium-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets J Nucl Med 35 1994 282 288
89. Ben-Haim S Kahn D Weiner GJ The safety and pharmacokinetics in adult subjects of an intravenously administered 99mTc-labeled 17 aminoacid peptide (CYT-379) Nucl Med Biol 21 1994 131 142
90. Pearson DA Lister-James McBride WJ Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies J Med Chem 39 1996 1372 1382
91. Lister-James J Knight LC Maurer AH Thrombus imaging with a technetium-99m-labeled activated platelet receptor-binding peptide J Nucl Med 37 1996 775 781
92. Muto P Lastoria S Varrella P Detecting deep venous thrombosis with technetium-99m-labeled synthetic peptide P280 J Nucl Med 36 1995 1384 1391
93. Lastoria S Vergara E Varrella P Imaging of thromboembolism by scintigraphy with the 99m-technetium-labelled synthetic peptide P280 Radiol Med (Torino) 90 1995 812 819
94. Taillefer R Thérasse E Turpin S Comparison of early and delayed scintigraphy with 99mTc-Apcitide and correlation with contrast-enhanced venography in detection of acute deep vein thrombosis J Nucl Med 40 1999 2029 2035
95. Liu S Edwards DS Loody RJ Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with 99mTc using aminocarboxylates as coligands Bioconjug Chem 7 1996 63 71
96. 99mTc]chelator-peptide conjugates Bioconjug Chem 7 1996 196 202
97. 99mTc Bioconjug Chem 8 1997 146 154
98. Oyen WJG Boerman OC Brouwers FM Scintigraphic detection of acute experimental endocarditis with the technetium-99m labeled glycoprotein IIb/IIIa receptor antagonist DMP444 Eur J Nucl Med 27 2000 392 399
99. 99mTc-labeled fibrin α-chain peptide J Nucl Med 41 2000 161 168